Universidad Fraternidad de Agrupaciones Santo Tomás de Aquino

Recent papers from Universidad Fraternidad de Agrupaciones Santo Tomás de Aquino

1. In Vivo Gene Editing of PCSK9 in the Prevention of Atherosclerotic Cardiovascular Disease: From Genetic Validation to Clinical ApplicationRevista Argentina de Cardiología · 2026
2. Implementation gaps in secondary prevention between coronary and cerebrovascular disease: a multicenter real-world studyEuropean Heart Journal · 2026
3. Efficacy of enlicitide, an oral PCSK9 inhibitor, across baseline Lp(a) strata in an analysis of two phase 3 trialsEuropean Heart Journal · 2026
4. The hidden atherogenic burden of lipoprotein(a): Reclassification by risk-weighted apoB in a multicenter registryAtherosclerosis · 2026
5. Double-Hit Genetic Dyslipidemia and Lifelong Cumulative Apob Exposure Driving Diffuse Polyvascular AtherosclerosisAtherosclerosis · 2026
6. Lp(a) Testing Awareness and Practices Among Latin American (Latam) Physicians Who Belong to Medical Societies: A Missed Opportunity in Cardiovascular Prevention.Atherosclerosis · 2026
7. Familial Hypercholesterolemia in Latin America: Unmet Needs, Barriers, and ChallengesJournal of Lipid and Atherosclerosis · 2026
8. Oxytetracycline on the Wetland Macrophyte Bidens laevis L. Seedlings: Uptake, Bioaccumulation, Translocation and Biochemical Stress ResponsesPlants · 2026
9. Prevalence of Elevated Lipoprotein(a) and Its Association with Cardiovascular Disease in Patients with Overweight and Obesity in ArgentinaDiabetes Metabolic Syndrome and Obesity · 2026
10. Elevated Lipoprotein(a) and Prevalent Cardiovascular Disease Burden in Treated HypertensionJournal of clinical lipidology · 2026
11. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin TherapiesJournal of the American College of Cardiology · 2026
12. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registryEuropean Heart Journal · 2025
13. Blood Pressure Control Unmasks the Cardiovascular Risk Associated With Lipoprotein(a): Insights From the Gaelp(a) StudyJournal of Hypertension · 2026
14. Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registryEuropean Journal of Preventive Cardiology · 2026
15. Interpreting the PISCES Trial on Fish Oil in Hemodialysis Patients: Lessons on Trial Design, Biological Exposure, and Outcome MeasurementClinical Kidney Journal · 2026
16. Comprehensive evaluation of enrofloxacin removal and toxicokinetic dynamics in Typha latifolia L.: Uptake, bioaccumulation, elimination, biotransformation, and plant responsesThe Science of The Total Environment · 2026
17. Lp(a) Testing in Latin America: Low Awareness and Clinicalpractice Among Medical Society Physicians Highlight a Missed Opportunity in Cardiovascular PreventionBMC Cardiovascular Disorders · 2025
18. Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemiaCurrent Opinion in Endocrinology Diabetes and Obesity · 2025
19. A multi-society Delphi consensus statement on the diagnosis of familial chylomicronemia syndrome.2025
20. Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysisAtherosclerosis · 2025